RT Journal Article
T1 Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study.
A1 Hernández, Domingo
A1 Ruiz-Esteban, Pedro
A1 Gaitán, Daniel
A1 Burgos, Dolores
A1 Mazuecos, Auxiliadora
A1 Collantes, Rocío
A1 Briceño, Eva
A1 Palma, Eulalia
A1 Cabello, Mercedes
A1 González-Molina, Miguel
A1 De Mora, Manuel
K1 Everolimus
K1 Left ventricular hupertrophy
K1 Renin-angiotensis blockers
K1 Sirolimus
K1 Kidney transplantation
K1 Inhibidores de la enzima convertidora de angiotensina
K1 Farmacoterapia combinada
K1 Hipertrofia ventricular izquierda
K1 Inmunosupresores
K1 Trasplante de riñón
K1 Inhibidores de proteínas cinasas
K1 TOR serina-treonina cinasas
K1 Resultado del tratamiento
K1 Antagonistas de receptores de angiotensina
AB BACKGROUNDLeft ventricular hypertrophy (LVH) is common in kidney transplant (KT) recipients. LVH is associated with a worse outcome, though m-TOR therapy may help to revert this complication. We therefore conducted a longitudinal study to assess morphological and functional echocardiographic changes after conversion from CNI to m-TOR inhibitor drugs in nondiabetic KT patients who had previously received RAS blockers during the follow-up.METHODSWe undertook a 1-year nonrandomized controlled study in 30 non-diabetic KT patients who were converted from calcineurin inhibitor (CNI) to m-TOR therapy. A control group received immunosuppressive therapy based on CNIs. Two echocardiograms were done during the follow-up.RESULTSNineteen patients were switched to SRL and 11 to EVL. The m-TOR group showed a significant reduction in LVMi after 1 year (from 62 ± 22 to 55 ± 20 g/m2.7; P=0.003, paired t-test). A higher proportion of patients showing LVMi reduction was observed in the m-TOR group (53.3 versus 29.3%, P=0.048) at the study end. In addition, only 56% of the m-TOR patients had LVH at the study end compared to 77% of the control group (P=0.047). A significant change from baseline in deceleration time in early diastole was observed in the m-TOR group compared with the control group (P=0.019).CONCLUSIONSSwitching from CNI to m-TOR therapy in non-diabetic KT patients may regress LVH, independently of blood pressure changes and follow-up time. This suggests a direct non-hemodynamic effect of m-TOR drugs on cardiac mass.
PB BioMed Central
YR 2014
FD 2014-04-23
LK http://hdl.handle.net/10668/2043
UL http://hdl.handle.net/10668/2043
LA en
NO Hernández D, Ruiz-Esteban P, Gaitán D, Burgos D, Mazuecos A, Collantes R, et al. Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study. BMC Nephrol. 2014; 15:65
NO Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 18, 2025